Glenmark Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE935A01035
  • NSEID: GLENMARK
  • BSEID: 532296
INR
1,968.20
-5.6 (-0.28%)
BSENSE

Dec 05

BSE+NSE Vol: 4.41 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,968.20",
    "chg": -5.6,
    "chgp": "-0.28%",
    "dir": -1,
    "prev_price": "1,973.80",
    "mcapval": "55,848.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE935A01035",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "4.41 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glenmark-pharma-780863-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Sees Robust Call Option Activity Ahead of December Expiry",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-surge-in-call-option-activity-amid-bullish-momentum-3733338",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_most_active_stocks_calls_3733338.png",
        "date": "2025-11-27 10:00:25",
        "description": "Glenmark Pharmaceuticals Ltd. has emerged as a focal point in the derivatives market with significant call option activity observed for the 30 December 2025 expiry. The pharmaceutical company’s stock has demonstrated notable price movements and trading patterns, attracting investor interest in bullish call options at the ₹1960 strike price, signalling market participants’ positioning ahead of the year-end."
      },
      {
        "title": "Why is Glenmark Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glenmark-pharma-fallingrising-3732208",
        "imagepath": "",
        "date": "2025-11-27 00:46:47",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Outperformance</strong></p>\n<p>The stock has demonstrated notable momentum, gaining 4.53% over the past week compared to the Sensex’s modest 0.50% rise. Over the last month, Glenmark outpaced the benchmark with a 5.77% increase against Sensex’s 1.66%. Year-to-date, the stock has surged 19.56%, doubling the Sensex’s 9.56% gain. This outperformance extends over longer horizons as well, with a remarkable 26.52% return in the past year compared to the Sensex’s 7.01%, and an extraordinary 350.89% gain over three years versus the benchmark’s 37.43%.</p>\n<p>On the day in question, Glenmark’s shares touched an intraday high of ₹1,927.10, marking a 2.43% increase. The stock has been on a two-day winning streak, delivering a cumulative 4.48% return in this period. It a..."
      },
      {
        "title": "Glenmark Pharma's Evaluation Revised Amid Strong Financial and Market Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glenmark-pharma-upgraded-to-strong-buy-by-marketsmojo-on-6-june-2025-3731110",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharma_mojoScore_3731110.png",
        "date": "2025-11-26 09:46:01",
        "description": "Glenmark Pharma has experienced a revision in its market evaluation, reflecting notable developments across its financial health, valuation, technical outlook, and overall quality. This shift highlights the company's evolving position within the Pharmaceuticals & Biotechnology sector and its growing appeal among investors."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Heavy Call Option Activity Amid Bullish Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-surge-in-call-option-activity-amid-bullish-market-sentiment-3728859",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_most_active_stocks_calls_3728859.png",
        "date": "2025-11-25 11:00:10",
        "description": "Glenmark Pharmaceuticals Ltd. has emerged as one of the most actively traded stocks in the call options segment, reflecting a notable bullish positioning among investors. The pharmaceutical company’s stock demonstrated resilience with a positive day’s return, outperforming its sector and broader market indices, while call option contracts at the 1900 strike price attracted significant trading volume ahead of the 25 November 2025 expiry."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3721300",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_oi_spurts_by_underlying_3721300.png",
        "date": "2025-11-21 15:00:56",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a significant rise in open interest within its derivatives segment, signalling a shift in market positioning and investor sentiment. This development comes amid a backdrop of subdued price movement and fluctuating volume patterns, prompting a closer examination of the underlying market dynamics and potential directional bets."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3721161",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_oi_spurts_by_underlying_3721161.png",
        "date": "2025-11-21 14:00:46",
        "description": "Glenmark Pharmaceuticals Ltd. has registered a significant rise in open interest within its derivatives segment, reflecting a shift in market positioning despite a modest decline in its share price. This development comes amid subdued investor participation and mixed technical indicators, prompting a closer examination of the stock’s trading dynamics and potential directional bets."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-price-action-3721031",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_oi_spurts_by_underlying_3721031.png",
        "date": "2025-11-21 13:00:31",
        "description": "Glenmark Pharmaceuticals Ltd. has experienced a significant rise in open interest within its derivatives segment, signalling heightened market engagement and evolving positioning among traders. This development comes amid a backdrop of mixed price movements and sector-level dynamics, prompting closer scrutiny of volume patterns and potential directional bets in the pharmaceutical space."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-mixed-market-signals-3720909",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_oi_spurts_by_underlying_3720909.png",
        "date": "2025-11-21 12:00:19",
        "description": "Glenmark Pharmaceuticals has experienced a significant rise in open interest within its derivatives segment, reflecting evolving market positioning and investor sentiment. Despite a modest decline in the stock price, the surge in open interest and trading volumes suggests active participation in futures and options, signalling potential directional bets by market participants."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Robust Call Option Activity Ahead of November Expiry",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-surge-in-call-option-activity-ahead-of-november-expiry-3720318",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlenmarkPharmac_most_active_stocks_calls_3720318.png",
        "date": "2025-11-21 10:00:16",
        "description": "Glenmark Pharmaceuticals Ltd. has emerged as a focal point in the options market with significant call option activity observed ahead of the 25 November 2025 expiry. The pharmaceutical company’s stock has demonstrated resilience in recent sessions, supported by notable trading volumes and open interest in call contracts, signalling a bullish sentiment among market participants."
      }
    ],
    "total": 450,
    "sid": "780863",
    "stock_news_url": "https://www.marketsmojo.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled \"Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP,",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Press Release",
      "datetime": "26-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding Grant of 20000 Options.",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - ESOP/ESOS/ESPS",
      "datetime": "15-Nov-2019"
    },
    {
      "details": "Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015",
      "source": "NSE",
      "caption": "Glenmark Pharmaceuticals Limited - Trading Window",
      "datetime": "06-Nov-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 03 Oct 25",
          "dt": "2025-10-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

Why is Glenmark Pharma falling/rising?

2025-11-27 00:46:47

Recent Price Movement and Market Outperformance

The stock has demonstrated notable momentum, gaining 4.53% over the past week compared to the Sensex’s modest 0.50% rise. Over the last month, Glenmark outpaced the benchmark with a 5.77% increase against Sensex’s 1.66%. Year-to-date, the stock has surged 19.56%, doubling the Sensex’s 9.56% gain. This outperformance extends over longer horizons as well, with a remarkable 26.52% return in the past year compared to the Sensex’s 7.01%, and an extraordinary 350.89% gain over three years versus the benchmark’s 37.43%.

On the day in question, Glenmark’s shares touched an intraday high of ₹1,927.10, marking a 2.43% increase. The stock has been on a two-day winning streak, delivering a cumulative 4.48% return in this period. It a...

Read More
stock-recommendationAnnouncement

Glenmark Pharmaceuticals Limited - Press Release

26-Nov-2019 | Source : NSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 26, 2019, titled "Glenmark Pharmaceuticals receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP,

Glenmark Pharmaceuticals Limited - ESOP/ESOS/ESPS

15-Nov-2019 | Source : NSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding Grant of 20000 Options.

Glenmark Pharmaceuticals Limited - Trading Window

06-Nov-2019 | Source : NSE

Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Glenmark Pharmaceuticals Ltd. has declared 250% dividend, ex-date: 03 Oct 25

stock-summary
SPLITS

Glenmark Pharmaceuticals Ltd. has announced 1:2 stock split, ex-date: 10 Sep 07

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available